Methylphenidate in Neuropsychological Sequelae of Radiotherapy and Chemotherapy of Childhood Brain Tumors and Leukemia

DeLong, Robert; Friedman, Henry T.; Friedman, Nancy; Gustafson, Kathryn E.; Oakes, Jerry

doi:10.1177/088307389200700425

Cited by 56 publications

(22 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two preliminary reports were among the first to investigate the use of MPH in children with learning problems presumably secondary to their cancer treatment. DeLong et al [78] at Duke University Medical Center treated 12 children surviving malignant brain tumours or ALL with MPH for 6 months to 6 years (median 23 months) and found that eight children had a 'good' response, two had a 'fair' response and two had a 'poor' response. No dosing information was given in their report.…”

Section: Methylphenidate and Cancermentioning

confidence: 98%

ReviewNeurocognitive sequelae of childhood cancers and their treatment

Mulhern

Butler

2004

Pediatric Rehabilitation

174

133

View full text Add to dashboard Cite

The present review will focus on the neurocognitive aspects of the medical treatment of childhood cancer by discussing current knowledge of brain damage among patients and how it is reflected in their cognitive abilities. It will direct these efforts toward the two most common forms of childhood cancer, acute lymphoblastic leukaemia (ALL) and brain tumours. It will first provide the reader with a brief medical background followed by a review of the current literature. The literature review will provide an in-depth analysis of the types of cognitive impairments observed and known or suspected risk factors for impairments. Finally, the review will close with a section that discusses interventions with the potential to prevent or minimize cognitive deficits acquired in the course of cancer treatment as they impact on the quality of life of paediatric cancer survivors.

show abstract

Section: Methylphenidate and Cancermentioning

confidence: 98%

ReviewNeurocognitive sequelae of childhood cancers and their treatment

Mulhern

Butler

2004

Pediatric Rehabilitation

174

133

View full text Add to dashboard Cite

show abstract

“…33 In another case series of 12 children with brain tumors or acute lymphocytic leukemia with associated neurologic injury, treatment with methylphenidate was associated with an improvement in attention, academic performance, language skills, memory, or behavior in 10 of 12 patients. 34 MP was also reported to improve shortterm cognitive function in 14 patients with advanced cancer and hypoactive delirium. 35 Similar outcomes were reported in two additional smaller case series involving five and three patients, respectively 22,36 and also in a single case report.…”

Section: Cognitionmentioning

confidence: 94%

Use of methylphenidate in patients with cancer

Sood

Barton

Loprinzi

2006

Am J Hosp Palliat Care

View full text Add to dashboard Cite

Cancer and its treatment are often associated with symptoms such as depression, somnolence, cognitive abnormalities, and fatigue. Methylphenidate, a stimulant medication, is commonly used to treat these symptoms. Several small pilot and a few adequately powered studies have assessed the safety and efficacy of methylphenidate in patients with cancer Overall, the studies so far suggest that methylphenidate is well-tolerated in patients with cancer Further, the studies have provided initial evidence of efficacy of this agent in patients with cancer The present article reviews the evidence base behind the use of methylphenidate in these patients.

show abstract

“…Methylphenidate (MPH) has been used for children with attentiondeficit/hyperactivity disorder without a history of cancer. For the past 20 years, investigators have been studying the drug among childhood cancer survivors to improve functioning [47][48][49][50][51][52][53][54]. A case series demonstrated a mixed response to MPH [49].…”

Section: Cognition: Pharmacotherapy Interventionsmentioning

confidence: 97%

Rehabilitation for survivors of pediatric brain tumors: our work has just begun

2009

View full text Add to dashboard Cite

CNS tumors are the second most common childhood cancer, and survival rates for children with these tumors have increased over the last few decades. Children are often treated with a combination of neurosurgery, chemotherapy and cranial radiation. Both the tumors and these therapies can lead to cognitive challenges, decreased social participation or coping, and physical dysfunction, which can impede a child’s ability to complete daily activities and participate in his or her environment. This review describes these late effects in the framework of the International Classification of Functioning, Disability and Health, and discusses the few studies that have attempted to improve children’s functioning in their environment beyond just survival.

show abstract

Methylphenidate in Neuropsychological Sequelae of Radiotherapy and Chemotherapy of Childhood Brain Tumors and Leukemia

Cited by 56 publications

References 9 publications

ReviewNeurocognitive sequelae of childhood cancers and their treatment

ReviewNeurocognitive sequelae of childhood cancers and their treatment

Use of methylphenidate in patients with cancer

Rehabilitation for survivors of pediatric brain tumors: our work has just begun

Contact Info

Product

Resources

About